Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers examine rare Post-Transplant cancer to improve future care

NCT ID NCT06422715

Knowledge-focused Sponsor: Fondazione Italiana Linfomi - ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviews medical records of 241 adults who developed a rare cancer called PTLD after an organ or stem cell transplant. Researchers aim to understand patient survival, disease features, and current treatments. No new treatments are tested; the goal is to gather information to design better future studies and therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

241 people

The number who actually took part.

Started

Oct 2024

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Population will be composed by patients with histological diagnosis of PTLD. The following clinical characteristics of the patient at the diagnosis of PTLD and pathology will be taken into consideration: positivity of EBV virus, serum LDH concentration, PTLD subtype (early lesion, polymorphic or monomorphic PTLD), lymphoma histotype, stage of disease according to the Ann Arbor classification and localization (nodal or extranodal), immunosuppressive regimen taken by the patient since the transplant, therapeutic approach adopted and response obtained.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * histological diagnosis of PTLD obtained from a biopsy sample (availability of stocked biopsy sample is requested but not mandatory); * age over 18 years at time of diagnosis of PTLD; * previously subjected to allogeneic transplantation (both SOT and HSCT); * diagnosis of PTLD obtained in 10 years' time frame (from 01/01/2011 to 31/12/2021); * free and voluntary written informed consent (included unreachable subjects according to Art. 36 UE Regulation 2016/679 and to the current Italian Privacy Regulation). Exclusion Criteria: * Patients not meeting the above-mentioned inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PTLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphoproliferative syndrome post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PTLD

Contacts and locations

Locations

  • A.O. Città della Salute e della Scienza - Ematologia Universitaria

    Torino, Italy

  • A.O. S. Croce e Carle - S.C. di Ematologia e Trapianto di Midollo Osseo

    Cuneo, Italy

  • A.O. Spedali Civili di Brescia - Ematologia

    Brescia, Italy

  • A.O. UNIVERSITARIA CAREGGI DI FIRENZE - Unità funzionale di Ematologia

    Florence, 50139, Italy

  • A.O. UNIVERSITARIA CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - SC Ematologia

    Torino, 10126, Italy

  • A.O. UNIVERSITARIA POLICLINICO S.ORSOLA-MALPIGHI DI BOLOGNA - Istituto di Ematologia "Seragnoli"

    Bologna, 40138, Italy

  • AOU Maggiore della Caritа di Novara - SCDU Ematologia

    Novara, Italy

  • AOU Senese - U.O.C. Ematologia

    Siena, 53100, Italy

  • ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

    Miano, Italy

  • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia

    Bergamo, 24127, Italy

  • Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Clinica Ematologica

    Udine, 33100, Italy

  • Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati

    Aviano, Italy

  • Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia

    Roma, 00161, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Ematologia

    Milan, MI, 20122, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica S. Cuore - Ematologia

    Roma, Italy

  • IRCCS ISTITUTO ONCOLOGICO VENETO (IOV) - Oncologia 1

    Padova, 35128, Italy

  • IRCCS Policlinico San Matteo - Divisione di Ematologia

    Pavia, Italy

  • Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia

    Milan, 20132, Italy

  • Ospedale Businco - Divisione di Ematologia

    Cagliari, Italy

  • Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare

    Roma, 00128, Italy

  • ULSS 8 Berica - Ospedale S. Bortolo - Ematologia

    Vicenza, 36100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.